- Home
- FHTX vs PVBC Comparison
FHTX vs PVBC Comparison
Compare FHTX & PVBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHTX
- PVBC
- Stock Information
- Founded
- FHTX 2015
- PVBC 1913
- Country
- FHTX United States
- PVBC United States
- Employees
- FHTX N/A
- PVBC N/A
- Industry
- FHTX Medicinal Chemicals and Botanical Products
- PVBC Major Banks
- Sector
- FHTX Health Care
- PVBC Finance
- Exchange
- FHTX Nasdaq
- PVBC Nasdaq
- Market Cap
- FHTX 278.1M
- PVBC 223.5M
- IPO Year
- FHTX 2020
- PVBC 2015
- Fundamental
- Price
- FHTX $5.06
- PVBC $12.96
- Analyst Decision
- FHTX Strong Buy
- PVBC Hold
- Analyst Count
- FHTX 6
- PVBC 1
- Target Price
- FHTX $11.33
- PVBC $12.50
- AVG Volume (30 Days)
- FHTX 87.3K
- PVBC 37.4K
- Earning Date
- FHTX 08-05-2025
- PVBC 10-23-2025
- Dividend Yield
- FHTX N/A
- PVBC N/A
- EPS Growth
- FHTX N/A
- PVBC 47.58
- EPS
- FHTX N/A
- PVBC 0.62
- Revenue
- FHTX $24,173,000.00
- PVBC $59,149,000.00
- Revenue This Year
- FHTX $43.75
- PVBC $9.73
- Revenue Next Year
- FHTX $1.27
- PVBC $4.87
- P/E Ratio
- FHTX N/A
- PVBC $20.85
- Revenue Growth
- FHTX N/A
- PVBC 0.70
- 52 Week Low
- FHTX $2.95
- PVBC $10.09
- 52 Week High
- FHTX $10.25
- PVBC $13.02
- Technical
- Relative Strength Index (RSI)
- FHTX 47.33
- PVBC 64.28
- Support Level
- FHTX $5.16
- PVBC $12.48
- Resistance Level
- FHTX $5.63
- PVBC $12.99
- Average True Range (ATR)
- FHTX 0.35
- PVBC 0.17
- MACD
- FHTX 0.01
- PVBC 0.04
- Stochastic Oscillator
- FHTX 38.83
- PVBC 90.00
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.